Skip to main content
. Author manuscript; available in PMC: 2018 May 5.
Published in final edited form as: Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9

Table 4.

Selected adverse events and quality of life of the approved agents

Drug Adverse events Improvement inquality of life? Reference
Axitinib Hypertension, diarrhoea, hypothyroidism and hand–foot syndrome Yes versus sorafenib 157
Bevacizumab Proteinuria, hypertension and bleeding Not reported 160
Cabozantinib Diarrhoea, hand–foot syndrome, hypertension, nausea and hypothyroidism Not reported
Everolimus Stomatitis, hypercholesterolaemia, hyperglycaemia and pneumonitis No versus placebo 209
Nivolumab Colitis, pneumonitis and endocrinopathies Yes versus everolimus 165
Pazopanib Diarrhoea, hypertension, liver function test abnormalities and hand–foot syndrome No versus placebo, Yes versus sunitinib 156
Sorafenib Hypertension, diarrhea, hand–foot syndrome and rash Yes versus placebo 154
Sunitinib Diarrhoea, hand–foot syndrome, mucositis and hypertension Yes versus IFN 155
Temsirolimus Stomatitis, hyperglycaemia, hypercholesterolaemia and oedema Yes versus IFN 210